<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prognosis for patients with <z:e sem="disease" ids="C0272199" disease_type="Neoplastic Process" abbrv="FHL|FEL|HPLH1|FHLH|HPLH|HLH1">familial hemophagocytic lymphohistiocytosis</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FHL</z:e>) is poor, but the survival of affected children has been markedly prolonged by treatment with the epipodophyllotoxin derivatives <z:chebi fb="0" ids="4911">etoposide</z:chebi> and teniposide and by bone marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Secondary malignancies</z:e> following epipodophyllotoxin therapy, including <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), have recently been reported </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a 9-year-old boy, treated with epipodophyllotoxins for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FHL</z:e> since he was 3 years old, who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>He was administered <z:chebi fb="0" ids="4911">etoposide</z:chebi> (cumulative doses of 6.9 g/m2 intravenously and 13.6 g/m2 orally) and teniposide (3.4 g/m2 intravenously), but no other systemic <z:chebi fb="0" ids="35610">antineoplastic drugs</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>This is, to our knowledge, the first report of a child with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FHL</z:e> developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> following administration of epipodophyllotoxins as the sole systemic chemotherapeutic drug has not been reported previously </plain></SENT>
<SENT sid="6" pm="."><plain>Supportive treatments, including the use of immunomodulating drugs, may reduce the risk for secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FHL</z:e> </plain></SENT>
</text></document>